What is Astec Lifesciences Ltd (ASTEC) share price return in the past 10 years?

Astec Lifesciences Ltd share price has appreciated 7.2% annually (CAGR) over the past ten years.

What is the share price of Astec Lifesciences Ltd (ASTEC)?

Company share prices are keep on changing according to the market conditions. The current trading price of Astec Lifesciences Ltd (ASTEC) on 02-Jul-2026 16:59:59 at 16:59 is 726.95.

What is the P/E ratio of Astec Lifesciences?

The latest standalone P/E ratio of Astec Lifesciences as of 02-Jul-2026 is 0.00.

What is the P/B ratio of Astec Lifesciences Ltd (ASTEC)?

The latest standalone P/B ratio of Astec Lifesciences Ltd (ASTEC) as of 02-Jul-2026 is 4.15.

What is the 52-week high and low of Astec Lifesciences Ltd (ASTEC)?

The 52-week high of Astec Lifesciences Ltd (ASTEC) is Rs. 979.05 and the 52-week low is Rs. 512.35.

Astec Lifesciences Ltd (ASTEC) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Astec Lifesciences Ltd (ASTEC)
Brand: Astec Lifesciences

Astec Lifesciences Ltd (ASTEC)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533138 NSE: ASTEC Pesticides & Agrochemicals | Small Cap | Astec Lifesciences Share Price

Astec Lifesciences Ltd (ASTEC)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533138 NSE: ASTEC Pesticides & Agrochemicals | Small Cap | Astec Lifesciences Share Price

Key Metrics

Valuation Multiples

Market Cap

₹1,620 Cr.

Current Price

₹727

52-Week Low / High

₹512 / 979

TTM EPS

₹-36.3

TTM Sales

₹448 Cr.

Book Value per Share

₹175.5

P/E Ratio

0.00

Industry PE

30.4

Price to Book (P/B)

4.14

Lower than its 5-year historical median

Price to Sales (P/S)

3.61

Lower than its 5-year historical median

EV/EBITDA

3773.45

Higher than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

-44.64%

Underperforms industry median

Return on Capital Employed (ROCE)

-12.62%

Underperforms industry median

Return on Assets (ROA)

-14.47%

Operating Profit Margin

-17.4%

Net Profit Margin

-35.33%

Gross Profit Margin

-25%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

-16.78%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

71.97%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹369 Cr.

Equity

₹22.3 Cr.

Face Value

₹10

All Time Low / High

₹14.35 / 2269.11

Astec Lifesciences stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Astec Lifesciences Ltd a good quality company?

Astec Lifesciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Astec Lifesciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Astec Lifesciences Ltd vs industry peers?

Astec Lifesciences Ltd revenue CAGR is -6.11%, compared to the industry median CAGR of 8.45%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Astec Lifesciences Ltd?

Promoters hold 71.97% of the Astec Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Astec Lifesciences Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 12.6% based on the current price.

DeciZen - make an informed investing decision on Astec Lifesciences

Consolidated basis

1. Right Stock

10 Year X-ray Pro

Long Term Prospect

2. Right Price

Price Chart

3. Right Time ⓘ

#Likely Future 5 Year CAGR.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	10.7%	16.1%	23.8%	20.3%	20.4%	22.3%	22.2%	7.8%	-4.5%	-12.6%	-
Value Creation Index ⓘ	-0.2	0.2	0.7	0.5	0.5	0.6	0.6	-0.5	-1.3	-1.9	-
Growth Parameters ⓘ
Sales ⓘ	247	299	368	431	523	555	677	628	458	381	448
Sales YoY Gr.	-	20.9%	23.1%	17.2%	21.3%	6.2%	21.9%	-7.2%	-27.1%	-16.8%	-
Adj EPS ⓘ	2.3	9.6	9.2	17.5	22.2	31.8	42.2	10.1	-25.5	-69.7	-36.3
YoY Gr.	-	324.7%	-5.1%	91.7%	26.5%	43.3%	32.9%	-76.1%	-352%	NA	-
BVPS (₹) ⓘ	59.9	69.9	85.8	102.4	124.8	156.5	200.7	212.2	186.8	118.8	175.5
Adj Net Profit ⓘ	4.5	18.9	18	34.6	43.7	62.7	83.4	20	-50.3	-138	-81
Cash Flow from Ops. ⓘ	-12.5	19.2	64.7	15.3	168	-8.2	23.6	74.7	10.2	-8.4	-
Debt/CF from Ops. ⓘ	-10.1	6.6	1.9	11.5	0.6	-22.9	11.8	4.6	48.3	-66	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.9%	-6.1%	-17.4%	-16.8%
Adj EPS ⓘ	-246.3%	-225.7%	-218.2%	NA
BVPSⓘ	7.9%	-1%	-16.1%	-36.4%
Share Price	7.2%	-11.7%	-18.2%	-22.5%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	3.5	14.8	11.7	18.6	19.5	22.6	23.6	4.9	-12.8	-45.6	-24.7
Op. Profit Mgn % ⓘ	13.9	21	18.7	17.8	16.3	20.1	22.8	12.2	-1.3	-17.4	-1
Net Profit Mgn % ⓘ	1.8	6.4	4.9	8	8.4	11.3	12.3	3.2	-11	-36.1	-18.1
Debt to Equity ⓘ	1.1	0.9	0.7	0.9	0.4	0.6	0.7	0.8	1.3	2.4	0.1
Working Cap Days ⓘ	304	248	233	223	217	229	244	316	379	368	174
Cash Conv. Cycle ⓘ	105	91	92	95	60	53	102	155	224	238	-4

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	247	299	368	431	523	555	677	628	458	381
Operating Expenses ⓘ +	215	236	299	354	437	443	522	552	464	448
Manufacturing Costs	19	22	25	32	39	38	52	64	54	59
Material Costs	161	180	235	279	339	342	387	401	319	297
Employee Cost	16	20	22	25	30	38	50	52	62	61
Other Costs ⓘ	20	14	17	17	30	25	33	35	29	31
Operating Profit ⓘ	32	62	69	76	85	111	154	76	-6	-66
Operating Profit Margin (%)	12.8%	20.9%	18.7%	17.7%	16.3%	20.1%	22.8%	12.1%	-1.3%	-17.4%
Other Income ⓘ +	7	3	8	11	12	8	10	13	6	6
Exceptional Items ⓘ	-3	-11	4	0	0	0	0	0	0	0
Interest ⓘ	13	12	11	12	13	5	9	21	25	37
Depreciation ⓘ	10	14	15	19	23	26	34	34	36	44
Profit Before Tax ⓘ	12	29	56	56	61	89	121	35	-62	-141
Tax ⓘ	7	10	21	20	14	24	31	9	-15	-6
Profit After Tax	5	19	35	36	48	65	90	26	-47	-135
PAT Margin (%)	2.1%	6.4%	9.5%	8.3%	9.1%	11.7%	13.3%	4.1%	-10.2%	-35.3%
Adjusted EPS (₹)	2.5	9.7	17.7	18.1	24.1	33.0	45.5	13.0	-23.8	-68.2
Dividend Payout Ratio (%)	0%	15.30%	8.40%	8.20%	6.20%	4.50%	3.30%	11.50%	0%	0%

Valuation of Astec Lifesciences - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	117	137	169	202	246	309	396	419	369	235
Share Capital ⓘ	19	20	20	20	20	20	20	20	20	20
Reserves ⓘ	98	118	149	182	226	289	377	399	349	215
Debt +	117	126	124	176	99	187	239	296	482	544
Long Term Debt	8	0	0	0	0	40	0	11	199	280
Short Term Debt	109	126	124	176	99	147	239	285	283	264
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	68	57	100	63	202	128	190	177	89	82
Others Liabilities ⓘ	25	13	20	20	24	53	100	87	35	26
Total Liabilities ⓘ	328	334	413	461	572	678	925	979	975	887
Fixed Assets
Net Fixed Assets ⓘ +	95	103	115	167	194	213	340	318	386	499
Gross Block	105	124	150	221	271	316	477	488	592	749
Accumulated Depreciation	10	22	35	54	77	103	137	170	206	250
CWIP ⓘ	20	8	42	19	24	116	23	127	165	21
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	71	66	78	93	121	106	187	295	196	160
Trade Receivables	81	111	123	122	161	187	274	155	169	147
Cash Equivalents	6	4	1	1	1	2	2	2	2	3
Others Assets ⓘ	55	43	53	59	70	54	100	82	57	57
Total Assets ⓘ	328	334	413	461	572	678	925	979	975	887

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-13	19	65	15	168	-8	24	75	10	-8
PBT ⓘ	12	29	56	56	61	89	121	35	-62	-141
Adjustment ⓘ	19	35	18	30	37	29	44	51	63	101
Changes in Working Capital ⓘ	-39	-38	6	-55	88	-103	-112	-6	10	27
Tax Paid ⓘ	-5	-7	-15	-16	-18	-23	-29	-5	-2	5
Cash Flow From Investing Activity ⓘ +	-16	-18	-49	-52	-74	-73	-104	-113	-135	-15
Capex	-26	-20	-50	-53	-45	-103	-104	-116	-135	-16
Net Investments	8	2	0	-0	0	-0	-0	-0	-0	-0
Others ⓘ	2	0	1	0	-29	29	0	4	0	1
Cash Flow From Financing Activity ⓘ +	31	-1	-18	37	-95	81	80	38	125	24
Net Proceeds from Shares ⓘ	0	0	0	0	0	1	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	40	0	16	105	90
Interest Paid ⓘ	-13	-12	-11	-12	-13	-5	-9	-20	-23	-29
Dividend Paid ⓘ	-3	0	-3	-3	-3	-3	-3	-3	-3	0
Others ⓘ	46	11	-5	52	-79	48	92	45	46	-38
Net Cash Flow ⓘ	2	1	-3	-0	0	0	0	-0	-0	0

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	4.01	15.07	22.9	19.31	21.24	23.46	25.5	6.28	-11.9	-44.64
ROCE (%)	10.65	16.08	23.75	20.31	20.44	22.29	22.21	7.75	-4.5	-12.62
Asset Turnover Ratio	0.72	0.95	0.99	0.99	1.02	0.89	0.85	0.66	0.47	0.42
PAT to CFO Conversion(x)	-2.6	1	1.86	0.42	3.5	-0.12	0.27	2.88	N/A	N/A
Working Capital Days
Receivable Days	136.10	111.40	115.10	103.30	98.10	113.70	123.70	123.90	128.70	148.30
Inventory Days	105.80	79.70	70.90	72.30	74.30	74.20	78.70	139.30	195	166.70
Payable Days	176.70	126.90	121.90	106.60	143.20	176.40	150	166.90	152.30	105

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Astec Lifesciences Ltd FAQs

The current trading price of Astec Lifesciences on 02-Jul-2026 16:59 is ₹727.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Astec Lifesciences stood at ₹1,619.9 Cr

The latest P/E ratio of Astec Lifesciences as of 01-Jul-2026 is 0.00.

The latest P/B ratio of Astec Lifesciences as of 01-Jul-2026 is 4.15.

The 52-week high of Astec Lifesciences is ₹979.0 and the 52-week low is ₹512.4.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astec Lifesciences is ₹448 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astec Lifesciences Ltd is a average quality company.

The key valuation ratios of Astec Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Astec Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Astec Lifesciences Ltd

Astec is proud of its rich experience of over two decades in the chemical industry. The company employs highly qualified and trained personnel to monitor and maintain its manufacturing activities as well as process development work. Astec prides itself in being responsive, reliable and quick to implement projects. A strong R&D focus has enabled the company to introduce a number of unique products. As the operations are highly integrated both vertically and horizontally, Astec has a very efficient, low cost structure in the market place.

Strong emphasis on quality, backed by a highly competent technical team, has enabled Astec to establish a successful track record in nurturing stable and long term relationships with highly reputed companies in USA, Japan and Europe. Above all, utmost respect for confidentiality, reliability, integrity and commitment in all its business relationships make Astec an ideal outsourcing partner. Astec Chemicals operates an ISO 9001:2000 certified Quality Assurance system.

The company has technologically sophisticated facilities for process development work and has demonstrated its ability to synthesize complex molecules rapidly. All its laboratories are equipped to carry out reactions from gm-scale to kilo-scale {up to 20 litres}.

Scale up to multikilo level is undertaken at its versatile 50-500 lts capacity pilot plant. Setting up a feasibility study through to laboratory development, pilot scale-up and full scale production are governed by the highest safety, quality and environmental standards.

Astec has multipurpose production facilities at two locations.

â€¢ Dombivli (50 km from Mumbai) â€¢ Mahad - two plants ( 180 kms from Mumbai)

They are multi-purpose plants based on 3,000-20,000 litres glasslined and stainless steel reactors. Typical reactors sizes are 10,000 lts.

â€¢ The pilot plant has glass and SS vessels of 50 litres to 500 litres capacity. â€¢ Reactions can be carried out from minus 20o C to 250o C. Distillation up to 300C â€¢ Vacuum down to 1mm Hg. â€¢ Distillation systems can handle high melting solids. â€¢ High efficiency fractionating columns up to 40 theoretical plates are available. â€¢ Facilities are designed to handle a number of corrosive and hazardous raw materials.

Products:

â€¢ Tebuconazole â€¢ Hexaconazole â€¢ Propiconazole â€¢ Metalaxyl â€¢ 1,2 Pentanediol â€¢ Dicap â€¢ 4-Fluoro phenacyl chloride.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Astec Lifesciences Ltd (ASTEC)

Astec Lifesciences Ltd (ASTEC)

Astec Lifesciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

DeciZen - make an informed investing decision on Astec Lifesciences

1. Right Stock

2. Right Price

3. Right Time ⓘ

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Astec Lifesciences - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Astec Lifesciences Ltd FAQs

What is the share price of Astec Lifesciences?

What is the market cap of Astec Lifesciences?

What is the P/E ratio of Astec Lifesciences?

What is the P/B ratio of Astec Lifesciences?

What is the 52-week high and low of Astec Lifesciences?

What is the TTM revenue of Astec Lifesciences?

Is Astec Lifesciences Ltd a good quality company?

Is Astec Lifesciences Ltd undervalued or overvalued?

Is Astec Lifesciences Ltd a good buy now?

About Astec Lifesciences Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.